Litcius/Paper detail

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

Brian J. Ward, А. И. Макарков, Annie Séguin, Stéphane Pillet, Sonia Trépanier, Jiwanjeet K. Dhaliwall, Michael Libman, Timo Vesikari, Nathalie Landry

2020The Lancet192 citationsDOI

Topics & Concepts

MedicinePlaceboSeasonal influenzaInfluenza A virusRandomized controlled trialVaccinationBody mass indexInfluenza vaccinePediatricsInternal medicineImmunologyVirusCoronavirus disease 2019 (COVID-19)DiseasePathologyInfectious disease (medical specialty)Alternative medicineTransgenic Plants and ApplicationsInfluenza Virus Research StudiesBacillus and Francisella bacterial research
Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials | Litcius